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Abstract
Falciparum malaria is a major parasitic disease causing widespread morbidity and mortality
globally. Artemisinin derivatives—the most effective and widely-used antimalarials that have
helped reduce the burden of malaria by 60% in some areas over the past decade—have re-
cently been found to induce growth retardation of blood-stage Plasmodium falciparum when
applied at clinically relevant concentrations. To date, no model has been designed to quantify
the growth retardation effect and to predict the influence of this property on in vivo parasite
killing. Here we introduce a mechanistic model of parasite growth from the ring to trophozoite
stage of the parasite’s life cycle, and by modelling the level of staining with an RNA-binding
dye, we demonstrate that the model is able to reproduce fluorescence distribution data from
in vitro experiments using the laboratory 3D7 strain. We quantify the dependence of growth
retardation on drug concentration and demonstrate the model’s utility as a platform to propose
experimentally-testable mechanisms of growth retardation. Furthermore we illustrate that a
drug-induced delay in growth may significantly influence in vivo parasite dynamics, demon-
strating the importance of considering growth retardation in the design of optimal artemisinin-
based dosing regimens.
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Introduction
Plasmodium falciparum malaria is a major parasitic disease which causes severe morbidity
and mortality in approximately half a million people annually [1]. Artemisinin (ART) and its
derivatives (e.g. artesunate, dihydroartemisinin and artemether), used in combination with part-
ner drugs, provide front-line protection, and have been responsible for dramatic reductions in
disease burden over the past few decades [1]. Despite their clinical and public health effective-
ness, the emergence of ART resistance and lack of alternative treatments places current control
programs at risk [2–5]. Development of a comprehensive understanding of ART’s mechanism
of action and associated effects on infected red blood cells (iRBCs) is therefore critical for
development of optimised ART-based treatment regimens and maintenance of control program
impact [6].
Recent in vitro experiments [7–9], combined with advances in pharmacokinetic–pharmacodynamic
(PK–PD) modelling [10], have established a platform to probe the parasite’s temporal response
to antimalarial drugs. The key experimental advance underlying these in vitro studies was the
application of short drug pulses, which enabled fine-scale measurement of the killing effect of
drug [10]. A normal life cycle of an iRBC for P. falciparum is approximately 48 hours and
is classified based on morphological appearance into three main stages: the ring stage (ap-
proximately 0–26 hours post infection (h p.i.)), trophozoite stage (approximately 27–38 h p.i.)
and schizont stage (approximately 39–48 h p.i.). Upon rupture at approximately 48 h p.i., iR-
BCs release merozoites, 8–12 of which successfully invade susceptible RBCs to initiate a new
round of infection [11–13]. Dogovski et al. demonstrated that a short pulse of ART (or dihy-
droartemisinin (DHA)) can induce growth retardation, prolonging the 48 hour life cycle [8].
Importantly, they found that growth retardation did not stop parasite growth entirely and was
thus considered to be distinct from parasite dormancy which “freezes” parasites for days to
weeks [14, 15].
Experimental identification of drug-induced growth retardation raises two questions: 1) By
how much is the life cycle of a parasite prolonged in response to a short drug exposure pulse?;
and 2) How influential is growth retardation when considering in vivo parasite killing using
PK–PD models? These two questions are important because we expect any drug-mediated
variation in the duration of one or more life stages to impact on the efficacy of the drug (given
the well-established finding that drug can exert stage-specific killing effect to parasites [7, 10,
16, 17].) The alteration in drug efficacy may be significant if the prolonged stage(s) covered
by the drug pulse exhibit very distinct killing effects. Quantification of growth retardation and
assessment of its potential effect on in vivo parasite killing is therefore important in guiding
further experimental investigations into drug activity and strategies for optimising ART-based
combination therapies.
To the best of our knowledge, no model has yet been designed to quantify the growth retar-
dation effect and predict its influence on in vivo parasite killing. Here we construct a mecha-
nistic model of parasite growth to explain drug-induced growth retardation. We model the rela-
tionship between parasite age and the fluorescence intensity of a parasite’s RNA/DNA-binding
dye. Through application to fluorescence data from in vitro experiments using the laboratory
3D7 strain by Dogovski et al. [8], we provide the first quantification of growth retardation.
We assess its dependence on drug (ART and DHA) concentration. We also suggest specific
alternative hypotheses for the mechanism of drug-induced growth retardation and demonstrate
that those mechanisms can be reliably identified in future experimental studies. Finally, by
incorporating growth retardation into a PK–PD modelling framework, we simulate in vivo par-
asite killing upon exposure to a single dose of artesunate and show how growth retardation may
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manifest as a phenotypical indication of drug-resistance.
Materials and Methods
Experiment and data
We first summarise the in vitro experiment in which parasite growth retardation was identified.
We provide sufficient information for the purposes of model development and evaluation. For
full details on the experimental implementation we refer the reader to the original publication
[8].
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Figure 1: Schematic diagram showing the experimental process. Cultured synchronised parasites (3D7
strain) either experience intraerythrocytic development without treatment (no drug) or were exposed to a
4h drug pulse at approximately 6 h p.i. (with drug). Upon rupture of infected RBCs, released merozoites
infect susceptible RBCs to initiate the second life cycle. At the time of data collection in the second life
cycle (which was carefully adjusted for an optimal observation of the bimodal fluorescence intensity
distribution), SYTO-61 fluorescence intensity data was collected and displayed using histograms (e.g.
presented in the box). Trophozoites exhibit higher fluorescence intensities than rings. It follows that the
left mode of the distribution primarily represents rings while the right one represents trophozoites. Any
change in the distribution indicates a possible drug-induced age retardation effect. Further details are
provided in the Materials and Methods.
Fig. 1 presents the experimental process. A culture containing tightly synchronised rings
(3D7 strain; over 80% of the population within a one-hour age window) with an average age
of 6 h p.i. was equally divided into a number of small cultures, each of which was treated with
a different concentration of drug (ART or DHA) for 4 hours. Two cultures unexposed to drug
acted as the control. The cultures were stained with SYTO-61 and examined by flow cytom-
etry [18]. SYTO-61 is a nucleic acid stain which stains both DNA and RNA and allows the
distinction of infected RBC from uninfected RBC, as well as distinguishing between parasite-
infected RBC of different ages due to an increase in nucleic acid content as the parasite ages.
SYTO-61 signals from all cultures were collected simultaneously at approximately 72 hours
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post drug administration (indicated in Fig. 1), corresponding to the period in which parasites
transition from the ring to trophozoite stage (during the second cycle). As trophozoites ex-
press significantly more nucleic acid, this period of transition exhibited a bimodal SYTO-61
fluorescence distribution. Quantitative analysis of this bimodal distribution is the key to our
approach as it enables us to identify the relative populations of parasites in the two successive
life stages [8]. As indicated in Fig. 1, if the administration of drug slows parasite growth then
the first life cycle would be prolonged and the second life cycle would start later. In conse-
quence, we would observe an increase in the ring population (i.e. the mode with the lower
fluorescence) and a corresponding decrease in the trophozoite population (i.e. the mode with
the higher fluorescence) in the SYTO-61 fluorescence histogram. Note that the underlying
processes of iRBC rupture and merozoite release and re-infection were not observable in the
experiment.
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Figure 2: SYTO-61 fluorescence frequency histograms with various ART concentrations (note that two
cultures with 0 nM ART were measured). For each panel, samples with fluorescence less than 3000
(indicated by the dashed lines) were taken to include fluorescence signals from uninfected RBC and
were thus excluded from the model fitting process. Note that the histograms are corrected by removing
the unviable population (see Materials and Methods for details).
The SYTO-61 fluorescence histograms often contain a small population of dead or dormant
parasites (due to drug activity or otherwise) that are not involved in the second life cycle. To
account for this non-viable population, a background experiment in which supermaximal drug
concentration (> 10× the 50% Lethal dose (3 days)) was applied for over 48 hours was also
performed [8]. The high drug concentration and long exposure time guaranteed that all parasites
became non-viable. Hence, denoting the SYTO-61 fluorescence frequency histogram under the
background condition by fb and the SYTO-61 fluorescence frequency histogram under a 4h
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drug pulse by f , the corrected SYTO-61 fluorescence frequency histogram, fc, is given by
fc = f − (1−V ) fb, (1)
where V represents the viability (the fraction of parasites entering the second life cycle; see
[7, 8] for details).
The corrected histogram data is shown in Fig. 2 (for various ART concentrations) and Sup-
plementary Fig. S1 (for various DHA concentrations). Experiments were performed in tech-
nical replicates for each drug concentration. The histograms in Fig. 2 present all available
SYTO-61 fluorescence intensity data. Also note that for each histogram, the samples with flu-
orescence intensity less than 3000 (indicated by the vertical dashed lines) were considered to
include fluorescence signals from uninfected RBCs and were thus excluded in the analysis.
Each histogram was generated by distributing log-transformed SYTO-61 fluorescence inten-
sity samples (with magnitude >3000) into 40 equally spaced bins. Raw SYTO-61 fluorescence
intensity data is provided in Dataset S1.
The model
Since the in vitro experiment measures the SYTO-61 fluorescence data in the second life cycle,
our model is designed to reproduce the underlying process of parasite growth over the period
of the ring-to-trophozoite transition in the second life cycle (see Fig. 1).
Over the period of the ring-to-trophozoite transition, the growth of individual parasites
is modelled by two sequential stages — an “immature” ring stage during which the ring-to-
trophozoite transition cannot occur (due to incomplete cellular development) followed by a
“mature” ring stage where the ring-to-trophozoite transition is possible — inspired by the clas-
sic model for the mammalian cell cycle [19, 20]. We introduce Ar, the ready-for-change age
(which is assumed to be the same for all parasites). Parasites of age a < Ar are, by definition,
rings. For parasites of age a>Ar, the waiting time before entering the trophozoite stage follows
a Poisson distribution with transition rate λ (denoted as Pois(λ )).
We assume that the age distribution of viable parasites (i.e. the parasites able to asexually
reproduce in the second life cycle) at the time of data collection is Gaussian (∼N(µ,σ 2)). This
is reasonable given that the parasites are tightly synchronised and drug is unlikely to differen-
tially kill parasites over such a tight age window (although a spreading in age distribution over
time was evident [8].)
The bimodal fluorescence intensity distributions (Fig. 2) suggest that both the SYTO-61
fluorescence intensity and the rate of increase in SYTO-61 fluorescence intensity is higher in
trophozoites than in rings. We model this property using a piecewise function mapping from
parasite age (a) to SYTO-61 fluorescence intensity (F) as follows:
F(a) =
{
F0er1a, a < Ac
F0er1Ac+r2(a−Ac), a≥ Ac
(2)
where Ac indicates the age of transition (from ring to trophozoite) for a parasite, noting that
each individual parasite’s Ac is sampled from Pois(λ ). Clearly Ac ≥ Ar for all parasites. For
each parasite, prior to the transition (i.e. a < Ac), the age-dependent intensity of SYTO-61
staining increases at a rate r1. Following the transition the rate increases to r2. We note that
although F0 gives the fluorescence intensity at the start of the second life cycle (i.e. age 0 h
p.i.), the model is not designed to study the early intraerythrocytic life-stages of the parasites.
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All model parameters are listed in Table 1. We note two important limiting cases of the
model. When Ar = 0, the model allows rings to transition to trophozoites immediately (at
0 h p.i.), with transition rate λ . On the other hand, when λ → ∞, all rings reaching age Ar
immediately undergo the transition to the trophozoite stage. Therefore, our model provides a
very general framework in which to study the statistics of the ring-to-trophozoite transition and
the mechanism of growth retardation.
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Figure 3: A single stochastic realisation of the model showing the evolution of both the age distribution
and SYTO-61 fluorescence distribution. The time change is indicated by the mean parasite age (i.e. µ).
The parameter values chosen for this example are σ = 0.8 h p.i., Ar = 21 h p.i., λ = 0.7 h p.i.−1, F0 = 20
(unitless), r1 = 0.24 h p.i.−1 and r2 = 0.56 h p.i.−1. The simulation starts with 4000 rings with a mean
age of 10 h p.i. and standard deviation of 0.8 h p.i.. The total number of parasites is shown in black and
the number of trophozoites in green.
In preparation for its application to the experimental data, Fig. 3 presents a single stochas-
tic realisation (performed using the Gillespie algorithm [21]) of the model. We initiated the
simulation with a population of 4000 ring-stage parasites with a mean age of 10 h p.i. (and
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standard deviation of 0.8 h p.i.) in the second life-cycle. We assumed that Ar = 21 h p.i.,
λ = 0.7 h p.i.−1, F0 = 20 (unitless), r1 = 0.24 h p.i.−1 and r2 = 0.56 h p.i.−1. Note that we
chose these parameters simply to illustrate the model’s behaviour. While the simulated fluores-
cence histograms may look similar to the experimental data, the parameters do not necessarily
represent the true values. The simulation was implemented in MATLAB (version R2014b;
The MathWorks, Natick, MA) and the code is provided in the Supporting Information. The
left panels in Fig. 3 show the continuous ageing of the parasite population and accumulation
of trophozoites within the simulated population. The right panels show how the transition to
a population dominated by trophozoites (with their corresponding increased SYTO-61 stain-
ing) leads to a distinct shift in the SYTO-61 fluorescence intensity histogram. The bimodality
evident in the observed data (Fig. 2) is also evident in the simulated data.
Table 1: A list of model parameters The unit h p.i. is an abbreviation of hour post-infection. We
assume in the model that the SYTO-61 fluorescence intensity is unitless.
Model pa-
rameter
Description Unit
µ mean of parasite age distribution at the time of data collection h p.i.
σ standard deviation of age distribution h p.i.
Ar the age before which the ring-to-trophozoite transition cannot oc-
cur
h p.i.
λ rate of conversion from ring to trophozoite h−1
F0 a parameter in the age-to-signal mapping (Eq. 2) –
r1 the rate at which the age-dependent intensity of SYTO-61 staining
increases in ring stage
[h p.i.]−1
r2 the rate at which the age-dependent intensity of SYTO-61 staining
increases in trophozoite stage
[h p.i.]−1
Derivation of the probability density function for the SYTO-61 fluores-
cence distribution
Our model for the transition from ring to trophozoite stage can be represented graphically by
mapping parasite age to SYTO-61 fluorescence intensity (Fig. 4). The intensity signal for a
single ring-stage parasite will increase with age along the line with slope r1. On becoming a
trophozoite (at a certain age Ac > Ar) it will then follow one of the green lines with slope r2. It
follows that a fluorescence intensity F1 can only originate from rings with age a1. However, a
fluorescence intensity F2 can result from trophozoites with ages between a2 and a′2 (inclusive)
or a ring with age a′2. These considerations suggest that we derive the probability density
function for the total fluorescence signal (from a population of parasites) in a piecewise way
with a critical point of separation, Fr, mapped from the ready-for-change age Ar.
Case 1: F ≤ Fr where Fr = F0er1Ar . Since a1 ∼ N(µ,σ 2) and a1 = ln(F/F0)/r1, we have the
probability density function for F ,
Pr(F) =
1
σ
√
2pi
e
− (a1−µ)
2
2σ2
(
1
r1F
)
, (3)
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Figure 4: Illustrative figure showing the mapping from parasite age to fluorescence intensity (in natural
logarithm). If a parasite is in ring form, it will move along the line with slope r1. Otherwise becoming a
trophozoite at a certain age after Ar will then follow a line with slope r2 (e.g. the green lines).
where 1/(r1F) is the derivative of a1 with respect to F due to use of the logarithmic transform
on the fluorescence data.
Case 2: F > Fr where Fr = F0er1Ar . The probability density function for F is a sum of two
parts. One is the probability of rings with age a′2 and the other is the probability of
trophozoites with a range of ages from a2 to a′2. The former is given by
Pr[F, from rings with age a = a′2] =
1
σ
√
2pi
e
− (a
′
2−µ)2
2σ2
[
e−λ (a
′
2−Ar)
]( 1
r1F
)
. (4)
The first term in this expression comes from the normal distribution of the population. The
second term follows from the modelled Poisson distribution, Pois(λ ), for the probability that a
parasite of age a′2 remains in ring form. The last term is the derivative of a′2 with respect to F
due to the logarithmic transform a′2 = ln(F/F0)/r1.
The contribution to the probability density from trophozoites is given by
Pr[F, from trophozoites] =
∫ a′2
a2
Pr(F|a)da, (5)
where Pr(F|a) is the probability density function of F from trophozoites with age a. To derive
Pr(F|a), we first give the cumulative probability∫ F+∆F
F
Pr(F|a)dF = 1
σ
√
2pi
e
− (a−µ)2
2σ2
[
e−λ (Ac(F+∆F)−Ar)− e−λ (Ac(F)−Ar)
]
, (6)
where Ac(F) = [r2a− ln(F/F0)]/(r2− r1) and
Ac(F +∆F) = [r2a− ln((F +∆F)/F0)]/(r2− r1). The difference of two exponentials
indicates the probability of trophozoites with conversion age between Ac(F) and Ac(F +∆F).
By multiplying 1/∆F on both sides of Eq. 6 and taking the limit ∆F → 0, we obtain
Pr(F|a) = 1
σ
√
2pi
e
− (a−µ)2
2σ2
[
λe−λ (Ac−Ar)
] 1
(r2− r1)F , (7)
where Ac = [r2a− ln(F/F0)]/(r2− r1). We notice that the second term λe−λ (Ac−Ar) is exactly
the probability density function of the Poisson distribution, and the last term is the derivative
of Ac with respect to F (except for a negative sign cancelled during simplification).
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Hence, the probability density function for F is given by
Pr(F) =


1
σ
√
2pi e
− (a1−µ)2
2σ2
(
1
r1F
)
, F ≤ Fr
1
σ
√
2pi e
− (a
′
2−µ)2
2σ2
[
e−λ (a
′
2−Ar)
](
1
r1F
)
+
∫ a′2
a2
Pr(F|a)da, F > Fr
(8)
where Pr(F|a) is given by Eq. 7, Fr = F0er1Ar , a1 = ln(F/F0)/r1, a2 = [ln(F/F0) + (r2 −
r1)Ar]/r2, a′2 = ln(F/F0)/r1 and Ac = [r2a− ln(F/F0)]/(r2−r1). Although a1 and a′2 have the
same expression, we retain both for clarity.
Parameter identifiability
To apply the analytical expression for the SYTO-61 fluorescence distribution (Eq. 8) to data, we
must determine if the equation is well-posed, i.e. is there sufficient information within the data
to uniquely identify the model’s parameters. Eq. 8 contains seven parameters, but as we will
now show, this equation can be reduced to an expression containing just five parameters. This
expression cannot be further reduced and so is sufficient for parameter estimation (Table 2).
The relationship between these five parameters and the seven “biological” parameters—with
which we are fundamentally concerned—is derived.
We begin with the case F < Fr and identify two new parameters,
K1 = ln(F0)+ r1µ, (9)
K2 = σr1. (10)
Pr(F) can be rearranged to be a two-parameter distribution
Pr(F) =
1
(σr1)
√
2pi
e
− [ln(F)−(ln(F0)+r1µ)]
2
2(σr1)2
(
1
F
)
=
1
K2
√
2pi
e
− [ln(F)−K1]
2
2K22
(
1
F
)
, (11)
where K1 and K2 represent the mean and standard deviation respectively. This is consistent
with the fact that a log-normal distribution is uniquely determined by two parameters.
Secondly, for the case of F > Fr, the first part is also a log-normal distribution except for a
Poisson probability density function. Thus we introduce
K3 = ln(F0)+ r1Ar, (12)
K4 =
λ
r1
, (13)
such that the first part is given by
1
σ
√
2pi
e
− (a
′
2−µ)2
2σ2
[
e−λ (a
′
2−Ar)
]( 1
r1F
)
=
1
K2
√
2pi
e
− [ln(F)−K1]2
2K22
[
e−K4(ln(F)−K3)
]( 1
F
)
. (14)
Thirdly, for the integral part, we introduce
K5 =
r2
r1
. (15)
Therefore, Eq. 7 becomes
Pr(F|a) = 1
K2
√
2pi
e
− (r1a+ln(F0)−K1)
2
2K22
(
e−Φ
) K4r1
(K5−1)F , (16)
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where
Φ = K4[K5(r1a+ ln(F0))− ln(F)+K3−K3K5]
K5−1
.
Then taking the transform b = r1a+ ln(F), the integral part in Eq. 8 becomes
∫ a′2
a2
Pr(F|a)da =
∫ b′2
b2
Pr(F|b)db =
∫ b′2
b2
1
K2
√
2pi
e
− [b−K1]2
2K22
(
e−Φ
) K4
(K5−1)F db, (17)
where
Φ = K4[K5b− ln(F)+K3−K3K5]
K5−1 ,
and the lower and upper bounds are given by
b2 =
ln(F)−K3 +K3K5
K5
and b′2 = ln(F).
At last, we find Fr = eK3 which finalises the process of expressing the fluorescence distri-
bution using five parameters, each of which should be identifiable by application of the model
to the fluorescence intensity histogram data. The final form of the model is given by
Pr(F) =


1
K2
√
2pi e
− [ln(F)−K1]2
2K22
( 1
F
)
, F ≤ eK3
1
K2
√
2pi e
− (ln(F)−K1)2
2K22
[
e−K4(ln(F)−K3)
]( 1
F
)
+
∫ b′2
b2 Pr(F|b)db, F > eK3
(18)
where the integral of Pr(F|b) is given by Eq. 17. A summary of the five new parameters is
provided in Table 2.
Table 2: A list of new parameters in the probability density function of the reduced fluorescence
intensity distribution. The new parameters are some combinations of the original model parameters
listed in Table 1 and are primarily used for data fitting. The choice of parameter constraints are provided
in the main text.
New parameter Relationship to the model parameters in Table 1 Constraint
K1 ln(F0)+ r1µ [6.2, 10.8]
K2 σr1 [0.0039, 1]
K3 ln(F0)+ r1Ar [2, 10.8]
K4 λ/r1 [0, 300]
K5 r2/r1 (1, 10]
Method for data fitting
The simplified 5-parameter probability density function (Eq. 18) was fitted to the observed
SYTO-61 fluorescence data for the 3D7 strain shown in Fig. 2 and Fig. S1. While drug induces
growth retardation of parasites in the first life cycle (from the time of drug exposure to the end
of that cycle), the second life cycle is drug-free and assumed to progress normally. Accordingly,
when modelling parasites in the second life cycle, the model parameter that may depend upon
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drug concentration is the mean parasite age µ (and thus K1 in the 5-parameter model). More-
over, since the parasite age distribution may change over time in the experiment, the spread of
parasite age distribution σ (and in turn K2) is also allowed to vary. To simultaneously fit the
model to all the data shown in Fig. 2 (or Fig. S1), we therefore require 35 parameters (16 for
K1, 16 for K2, and one for each of K3, K4 and K5).
To optimise the data fitting procedure, we provide plausible ranges for each parameter (sum-
marised in Table 1). Based on the observed fluorescence range of approximately 500–50000
in the observed data, we have eK1 ∈ [500,50000] which gives K1 ∈ [6.2,10.8]. We estimate
σ ∈ [0.39,2] The lower bound is based on the the estimated standard deviation of the initial
parasite age distribution where approximately 80% of parasites were aged within a one-hour
window centred at the mean age. The upper bound is chosen to allow for a much wider age
distribution. r1 is assumed to be in [0.01,0.5] where the lower bound avoids a very small
denominator in K4 and K5. These give K2 ∈ [0.0039,1]. We have K3 ∈ [2,10.8] based on a
similarity to K1 but with a much smaller lower bound in order to capture possible small values
of Ar. K4 ∈ [0,300] corresponds to λ ∈ [0,3] where the upper bound λ = 3 represents a very
fast ring-to-trophozoite transition (over 95% of rings become trophozoites within one hour of
ageing to the ready-for-change age Ar). We have K5 ∈ (1,10] where the lower bound is based
on the assumption that r2 > r1 and the upper bound is arbitrarily chosen.
A global search using a combination of Latin Hypercube Sampling (LHS) and non-linear
least squares optimisation was performed. A minimum of 4000 parameter sets (each of which
contains 35 parameter values, 16 identical values for K1, 16 identical values for K2, and one
value for each of K3, K4 and K5) were randomly generated using MATLAB’s built-in LHS
function lhsdesign (plus a few additional sets proposed based on our prior knowledge) and
were used as initial points for multi-start optimisation. The precision for the initial values was
up to the first decimal place for K2 and integer values were sampled for all other parameters. For
each of these initial points (minimum 4000) generated using the LHS sampling, MATLAB’s
built-in functions lsqcurvefit and nlparci with default settings were used to minimise the sum
of squared residuals subject to the above constraints and produce the corresponding best-fit
parameter values and associated 95% confidence intervals (CIs). The globally optimal solution
and associated best-fit parameter values (which are presented in the Results) were given by
the parameter set producing the smallest sum of squared residuals. The trapezoidal integration
method with a division of 1000 equal sub-intervals was used to approximate the integral over
[b2,b′2] in the probability density function.
Results
Quantifying the dependence of drug-induced parasite growth retardation
on drug concentration
Fig. 5 presents the results of fitting the 5-parameter model to the SYTO-61 fluorescence data
for ART (the best-fit parameter values are provided in Supplementary Table S1). The model
correctly captures the ART-dependent change of shape in SYTO-61 fluorescence histograms
— increasing ART concentration leads to an increase in the ring population (i.e. the mode with
the lower fluorescence) at the expense of a decreased trophozoite population (i.e. the mode
with the higher fluorescence).
To quantify the extent of ART-induced parasite growth retardation, we define T∆ = µ −
Ar, the time period (in the second life cycle) from the ready-for-change age Ar to the mean
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Figure 5: Results of fitting the model to SYTO-61 fluorescence frequency data with various ART
concentrations (note that two cultures with 0 nM ART were measured). The red curves represent the
best-fits to the histogram data. For each panel, the samples with intensity less than 3000 (indicated by
the dashed lines) were excluded from the model fitting process. Note that the histograms are corrected
by removing the unviable population (see Materials and Methods for details). Full fitting results are
provided in Supplementary Table S1.
population age at the time of data collection µ . Recapping Fig. 1, since the delay in rupture
time of the first cycle directly affects the mean parasite age at the time of data collection µ ,
but not the ready-for-change age Ar, the change in T∆ therefore provides a direct indication
of how much the rupture time is delayed in the first life cycle due to drug application. A
smaller T∆ indicates a longer delay in the rupture time (in the first cycle), i.e. parasites are
younger when measured. Conversely, a larger T∆ indicates a shorter delay, i.e. parasites are
relatively older at the time of data collection. Given that r1T∆ = K1 −K3 and that the age-
dependent SYTO-61 staining rate r1 is independent of drug concentration, we can use K1−
K3 to quantify the dependence of growth retardation on drug concentration. A smaller value
for K1 −K3 indicates a longer delay in the rupture time (in the first cycle). Fig. 6A shows
that, for an ART concentration of less than 5 nM (applied as a 4h pulse), little if any growth
retardation is evident. However, when ART concentration increases above 5 nM, K1−K3 (and
so T∆) decreases approximately linearly, implying an approximately linear positive correlation
between the delay to rupture time (for the first cycle) and drug concentration.
For clinically relevant DHA, the model performs similarly well (Fig. 7). Similar to ART,
we observe a region where parasite growth is almost unaffected (e.g. DHA less than 1 nM;
see Fig. 8A) followed by a region where K1 −K3 decreases monotonically with increasing
DHA concentration. However, unlike for ART, the relationship is non-linear. For high drug
concentration, K1 −K3 ceases to decrease (although this might be inaccurate due to limited
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Figure 6: Dependence of growth retardation and spread of parasite age distribution on applied ART
concentration. The extent of growth retardation is indicated by K1−K3. A smaller value for K1−K3
indicates a longer delay in the rupture time in the first cycle. The extent of spread of parasite age
distribution is indicated by K2. A larger K2 indicates a wider parasite age distribution. The horizontal
dashed line indicate the mean of all the estimates of K2. The vertical dotted lines separate the results of
“no drug” cases and “with drug” cases (for a proper display of the “no drug” cases).
numbers of samples caused by low viabilities), indicating some sort of saturation effect.
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Figure 7: Results of fitting the model to experimental data of SYTO-61 fluorescence frequency his-
tograms with various DHA concentrations (note that two cultures with 0 nM DHA were measured).
The red curves represent the best-fits to the histogram data. For each panel, the samples with intensity
less than 3000 (indicated by the dashed lines) were excluded in model fitting process. Note that the
histograms are corrected by removing the unviable population (see Materials and Methods for details).
Full fitting results are provided in Supplementary Table S2.
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Although we cannot determine T∆ from K1−K3 due to the unknown parameter r1 (the rate of
age-dependent SYTO-61 staining in ring stage), we can provide some useful bounds based on
plausible values for r1. For example, if r1 is 0.1 [h p.i.]−1 then an increase in ART concentration
from 0 nM to approximately 1000 nM leads to a decrease of K1−K3 from approximately 0.5 to
0.26 (Fig. 6A), implying a delay in rupture time of approximately T∆ = (0.5−0.26)/0.1= 2.4
hours. Similarly, for the same r1 value but an increase in DHA concentration from 0 nM to 100
nM (see Fig. 8A), the estimated delay in rupture time is approximately ((0.5−0.1)/0.1 =) 4
hours, which is longer than that induced by 1000nM ART. Clearly, if r1 is smaller (or larger),
the actual rupture time will be delayed (advanced) accordingly. Based on a reasonable range
for r1 of [0.05–0.25] h p.i.−1, the drug-induced delay in rupture time (for the first life cycle)
should be no more than 10 hours.
The parasite age distribution is relatively unaffected by the drug pulse
The parameter K2 (= σr1) directly indicates how the standard deviation (or spread) of the para-
site age distribution at the time of data collection (σ ) depends on drug concentration. As shown
in Figs. 6B and 8B, there is a weak positive correlation for relatively low drug concentrations.
For relatively high drug concentrations, although K2 drops substantially for DHA (Fig. 8B,
which might be strongly affected by small sample size), no substantial decrease is observed for
ART (Fig. 6B). These results suggest that, although varying drug concentration may affect the
spread of the parasite age distribution, the effect is usually very limited.
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Figure 8: Dependence of growth retardation and spread of parasite age distribution (indicated by K2)
on applied DHA concentration. The extent of growth retardation is indicated by K1−K3. A smaller
value for K1−K3 indicates a longer delay in the rupture time in the first cycle. The extent of spread of
parasite age distribution is indicated by K2. A larger K2 indicates a wider parasite age distribution. The
horizontal dashed line indicates the mean of all the estimates of K2. The vertical dotted line separates
the results of “no drug” cases and “with drug” cases.
New experiments to test alternative mechanisms for drug-induced growth
retardation
Having established that our model can be used to quantify the relationship between applied
drug concentration and growth retardation for the in vitro data, we now explore the utility of
the model for identifying possible alternative mechanisms responsible for growth retardation.
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Figure 9: Schematic diagram showing the proposed experiment for the identification of the possible
mechanisms of growth retardation, i.e. a decreased transition rate λ or a postponed ready-for-change
age Ar. The experiment is almost the same as the in vitro experiment introduced in the Materials and
Methods and Fig. 1. The only change is that the time of data collection is moved from the first to the
second life cycle, although we acknowledge potential experimental challenges due to the requirement
that only the signal from viable parasites is interpreted. The exact time of data collection depends on
further experimental adjustments and should capture the ring-to-trophozoite transition in the first life
cycle (and not overlap with the drug application window). Measured fluorescence histogram data (again
normalised) will be used for estimation of model parameters.
Focusing on the ring-to-trophozoite transition (which is the core part of the model), one hy-
pothesis is that growth retardation may be a result of either a decreased transition rate λ or a
postponed ready-for-change age Ar for parasites in the first life cycle (and thus delayed rup-
ture time and initiation of the second life cycle). To test the hypothesis, we would require
fluorescence intensity measurements for viable parasites to be performed during the first life
cycle, particularly around the period of the ring-to-trophozoite transition. Such an experimental
setup is illustrated in Fig. 9. We note that the in vitro data used thus far, in which fluorescence
measurements were taken in the second life cycle, were primarily designed to assess viability
(which is, of course, only measurable through study of the second life cycle.) and so are not
suitable for testing this hypothesis. We have therefore taken an in silico approach in anticipation
of future experimental studies.
First, suppose that increasing ART concentration decreases the ring-to-trophozoite transi-
tion rate λ (while leaving the ready-for-change age Ar unchanged). Fig. 10 shows simulated
data and the model fit for four different values of the transition rate λ between 0.3 and 1.2.
Simulated data is in black (generated by assuming 4000 parasites were present) and the best-fit
model in red (dashed lines). The true (model-based) distribution from which the simulated data
were obtained is shown in blue. Fig. 11 presents estimates for K3 and K4, which determine
Ar and λ respectively (Table 2). The model fitting procedure correctly identifies that Ar, the
ready-for-change age, was unchanged across the simulations, while λ , the ring-to-trophozoite
transition rate, was increased. We note the presence of some minor bias in the estimate for
16
10
3
10
4
10
5
N
o
. 
o
f 
e
v
e
n
ts
0
50
100
150
200
250
300
350
A
r
= 21 , λ = 0.3
simulated data
true distribution
best-fit distribution
10
3
0
4
	0
5
0
50

00
50
200
250
300
350
A
r
= 2 , λ = 0.6
simulated data
true distribution
best-fit distribution
0
3
0
4
0
5
0
50
00
50
200
250
300
350
A
r
= 2 , λ = 0.9
simulated data
true distribution
best-fit distribution
SYTO-6  fluorescence intensity
0
4
0
50
00
50
200
250
300
350
A
r
= 2 , λ = .2
simulated data
true distribution
best-fit distribution
Figure 10: Simulated data with both the true and best-fit distributions. 4000 samples were used for
each histogram. The values of Ar and λ used to generate the simulated data are indicted in each panel.
Other parameters are provided in Table S3. The true distribution is given by Eq. 18. The method for
data fitting is given in the Materials and Methods.
K3 for this particular simulated dataset. Supplementary Fig. S2 presents summary statistics for
100 replications of the simulation-reestimation procedure and establishes that unbiased esti-
mates were obtained. The relative bias for all 11 parameters (K1, K2, 4×K3, 4×K4, K5) was
very small, the largest being 1.03%).
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Figure 11: Comparison of best-fit parameter values and the true values for the simulated dataset shown
in Fig. 10. Error bars indicate 95% CIs of the estimates. Full fitting results are given in Supplementary
Table S3.
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In addition to varying λ only, we also examined the other three logical possibilities: 1) λ
is fixed and Ar is varied (see Figs. S3 and S4; Supplementary Table S4); 2) both λ and Ar are
varied but in opposite directions, i.e. one increases while the other decreases (see Figs. S5 and
S6; Supplementary Table S5); 3) both λ and Ar are varied but in the same direction, i.e. both
increase or decrease (see Figs. S7 and S8; Supplementary Table S6). In all situations, the results
consistently show that the possible variations in the key parameters λ and Ar are identified for
a given set of simulated fluorescence intensity histogram data. Hence, with future availability
of fluorescence data collected during the first cycle, we anticipate that our model will reliably
distinguish between the alternative hypothesised mechanisms driving growth retardation.
Predicting the effect of growth retardation on in vivo parasite killing
Although a short pulse (4 hours) of ART/DHA may prolong the parasite’s life cycle by a rela-
tively short time (e.g. less than 10 hours as estimated above), it could have a significant effect
on in vivo parasite killing. For example, if the delay occurs during the ring-to-trophozoite tran-
sition (as hypothesised above), then the recent identification that ring-stage parasites exhibit a
much lower sensitivity to ART (and DHA) than those in the trophozoite stage [7,16,17] directly
suggests that delayed ageing may lead to effective drug escape. Accordingly, here we perform
a preliminary investigation of the possible impact of growth retardation on in vivo parasite
killing using a simple PK–PD model. The model contains just two compartments representing
populations of rings and trophozoites, with a transition rate from rings to trophozoites given by
the rate λ . Rings are killed by ART/DHA at a slower rate than trophozoites, as suggested by
previous findings [7, 16, 17]. Model details are provided in the Supporting Information.
Simulation results are shown in Fig. 12. A population of ring-stage parasites were initially
distributed with a mean age of 10 h p.i. (note, this is simply the time since the simulated
population of RBCs were infected, not the time of clinical exposure for the simulated host) and
a standard deviation of 2 h at the start of simulation. With a single dose of artesunate (2mg/kg)
applied at 10 hours (see the middle panel of Fig. 12), the rate of parasite death for a scenario in
which there is no drug-induced growth retardation (i.e. λ is independent of drug concentration)
is significantly higher than that for a scenario in which there is drug-induced growth retardation
(i.e. λ is a function of drug concentration). Growth retardation delays the transition from
rings to trophozoites and in turn prevents those parasites from being killed as the drug’s short
half-life (approximately 0.9 h) allows them to avoid exposure during the trophozoite stage.
This result suggests that, if drug induces a slower transition from ring to trophozoite stage,
growth retardation has a substantial adverse effect on efficient parasite killing and may thus be
considered as a potential mechanism for decreasing ART sensitivity.
Discussion
In this paper, we have studied ART-induced parasite growth retardation using a mechanistic
model that considers the ring-to-trophozoite transition to be a two-stage process and exploits the
differing rates of nucleic acid production (measured through SYTO-61 fluorescence intensity)
in those two life stages. By fitting the model to fluorescence histogram data, we have been
able to identify the dependence of growth retardation on applied drug concentration (Figs.
6A and 8A) and obtain reliable estimates for how much the parasite’s life span is prolonged
due to exposure to drug. Our primary findings from this analysis were that: 1) drug-induced
parasite growth retardation exhibits a threshold-like behaviour such that growth retardation is
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Figure 12: Simulation of in vivo parasite killing under a single dose of artesunate. The simulation is
initiated with 1011 parasites initially distributed into 20 age bins from age 1 h p.i. to 20 h p.i. (we only
consider integer ages and note that h p.i. refers to the age of iRBCs, not the time of host infection)
following a normal distribution with a mean of 10 h p.i. and a standard deviation of 2 h p.i. at the start
of simulation (upper left panel). We let the population grow for 10 hours’ simulation time in order that
a mixed population of rings and trophozoites appeared when a single dose of artesunate was applied.
The pharmacokinetic profile of DHA (the active metabolite of artesunate) is given in the middle panel.
If the ring-to-trophozoite transition rate λ is assumed to be drug-independent (i.e. there is no drug-
induced growth retardation), the age distribution after 20 hours’ simulation (upper right panel) and the
parasite killing curve (lower panel) are shown in dark green. Results under the assumption that λ is
drug-dependent are shown in magenta.
evident only when drug concentration is sufficiently large (for example, > 10 nM ART for a
4 hour drug pulse); 2) the parasite life cycle is prolonged by no more than 10 hours due to
application of ART/DHA; and 3) the parasite age distribution at the time of data collection
in the second life cycle is relatively unaffected by the application of short drug pulses with
different concentrations.
Furthermore, we used the model to propose a hypothetical mechanism of ART-induced
parasite growth retardation. We considered growth retardation to be due to either a decreased
transition rate λ or a postponed ready-for-change age Ar, or a combination of the two. We have
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shown that, if fluorescence intensity data were collected in the first life cycle, that the model is
able to accurately identify the dependencies of the transition rate λ and the ready-for-change
age Ar on drug concentration. With the availability of new experimental data (e.g. fluorescence
data from the first life cycle), we will be able to incorporate growth retardation into our re-
cently developed dynamic-stress model of antimalarial action [10], providing a comprehensive
platform for the study and optimisation of ART-based therapies.
ART-induced growth retardation has two competing effects. Firstly, it slows the overall rate
of growth by extending the life cycle. However, by delaying the transition to the trophozoite
stage, the parasite avoids being exposed to drug at a highly sensitive stage [7, 10], providing
a net benefit (to the parasite) due to the delay (as shown in Fig. 12). Our preliminary in vivo
simulations suggest that the overall effect is likely to be strongly beneficial (for the parasite):
a short delay in the time of ring-to-trophozoite transition will have a minimal impact on the
overall growth rate (and so any implications for onwards transmission are likely minimal),
yet is extremely effective in avoiding the short ART/DHA pulse and so killing. Therefore,
understanding where in the parasite life cycle drug-induced growth retardation acts is important
in the context of combating emergent drug resistance through optimisation of dosing regimens,
as demonstrated by our in vivo simulations (Fig. 12). Furthermore, these results suggest that
developing new longer-lived ART derivatives may overcome resistance to ART and DHA, as a
direct consequence of their longer half lives.
Returning to the model we have introduced to analyse the SYTO-61 fluorescence data, it
provides a major advance on current methods used to study mixed histograms from fluorescence
assays. Current practice is to simply partition the bimodal signal into “low” and “high” com-
ponents at a chosen threshold intensity. While suitable for well separated peaks, this method is
inadequate for determining mixtures of rings and trophozoites as shown in Fig. 2. Our model
clearly dissects the contributions of different parasite populations to the fluorescence distribu-
tion (Eq. 18) where the integral part represents the contribution from trophozoites while the
sum of all other parts represents the contribution from rings. It can therefore be used to esti-
mate the fraction of parasite subpopulations based on fluorescence intensity distribution in a far
more reliable and rigorous way. Moreover, given that fluorescence dye staining is a standard
assay in experimental biology, we anticipate that our novel methods will be broadly applicable
to other problems, for example in the application to the adoptive transfer data utilised in [22].
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Supporting Information
The supporting information contains the following:
1. MATLAB code for the stochastic simulation shown in Fig. 3 in the main text
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MATLAB code for the stochastic simulation shown in Fig. 3 in the main
text
1 c l e a r
2 c l c
3 t i c
4
5 Ar = 2 1 ; % ready−f o r−change age
6 t o t a l N u m = 4 e +3; % t o t a l number o f v i a b l e p a r a i s t e s
7
8 i n i t t e m p = 0 . 8∗ r andn ( 1 , t o t a l N u m ) +10;
9 i n i t a g e = i n i t t e m p ( i n i t t e m p >=0) ; % i n i t i a l age d i s t r i b u t i o n
10 age = s o r t ( i n i t a g e ) ;
11 s t a g e = ( age>=Ar ) +1;
12 % s t a g e =1: r i n g s b e f o r e age Ar ; s t a g e =2: r i n g s a f t e r Ar ; s t a g e
=3: t r o p h
13 i n d e x = 1 : l e n g t h ( age ) ;
14
15 r and1 = rand ( 1 , l e n g t h ( s t a g e ) ) . ∗ ( s t a g e == 2) ;
16 Xi = l o g ( 1 . / r and1 ) ;
17 t r a c k i n g = z e r o s ( 1 , l e n g t h ( rand1 ) ) ; % t r a c k i n g v a r i a b l e
18
19 lambda0 = 0 . 7 ; % r i n g−to−t r o p h t r a n s i t i o n r a t e
20 lambda = ( s t a g e == 2) . ∗ lambda0 ;
21 a g e t o c h a n g e = t r a c k i n g ; % t h e a c t u a l age when a r i n g change
t o t r o p h
22
23 r1 = 0 . 2 4 ;
24 r2 = 0 . 5 6 ;
25 F0 = 2 0 ;
26
27 SYTO61 = F0∗exp ( r1 ∗ age ) ;
28
29 age0 =age ;
30 s t a g e 0 = s t a g e ;
31 SYTO610=SYTO61 ;
32
33 d t = 0 . 0 1 ;
34
35 t = 0 : d t : 2 0 ;
36
37 t i m e t o r e c o r d = 1 1 : 1 5 ; % r e c o r d t h e r e s u l t s o f mean age
=21 ,22 ,23 ,24 ,25
38
39 i n d e x t =1: l e n g t h ( t i m e t o r e c o r d ) ;
40
41 a g e a l l = ones ( l e n g t h ( t i m e t o r e c o r d ) , 1 ) ∗ age ;
42 s t a g e a l l = ones ( l e n g t h ( t i m e t o r e c o r d ) , 1 ) ∗ s t a g e ;
24
43 SYTO61 all= ones ( l e n g t h ( t i m e t o r e c o r d ) , 1 ) ∗SYTO61 ;
44
45 wb= w a i t b a r ( 0 , ’ p l e a s e w a i t ’ ) ;
46
47 f o r i = 2 : l e n g t h ( t )
48
49 % u p d a t e age
50 age = age + d t ;
51
52 % u p d a t e t h e s t a t u s f o r t h o s e whose r i n g−to−t r o p h
t r a n s i t i o n o c c u r s
53 t r a c k i n g = t r a c k i n g + lambda ∗ d t ;
54 t r s = ( t r a c k i n g−Xi>=0) ; % t r a n s i t i o n t o t r o p h o c c u r s
55 s t a g e = s t a g e + t r s ;
56 a g e t o c h a n g e = a g e t o c h a n g e + t r s . ∗ age ;
57 t r a c k i n g = t r a c k i n g .∗(1− t r s ) ; % u p d a t e t r a c k i n g v a r i a b l e
58 r and1 = rand1 .∗(1− t r s ) ;
59
60 % u p d a t e t h e s t a t u s o f t h e r e s t p a r a s i t e s
61 temp = age . ∗ ( s t a g e == 1) ;
62 ind temp = i n d e x ( temp>=Ar ) ;
63 r and1 ( ind temp ) = rand ( 1 , l e n g t h ( ind temp ) ) ;
64 Xi = l o g ( 1 . / r and1 ) ;
65 s t a g e ( ind temp ) = 2 ;
66 lambda = ( s t a g e == 2) . ∗ lambda0 ;
67
68 % SYTO61 f l u o c u m u l a t i o n
69 SYTO61 = ( s t a g e <3) . ∗ ( F0∗ exp ( r1 ∗ age ) ) + . . .
70 ( s t a g e ==3) . ∗ ( F0∗ exp ( r1 ∗ a g e t o c h a n g e ) . ∗ exp ( r2 ∗ ( age−
a g e t o c h a n g e ) ) ) ;
71
72 % r e c o r d i n g r e s u l t s
73 i n d t = i n d e x t ( t i m e t o r e c o r d == t ( i ) ) ;
74 i f ˜ i s e m p t y ( i n d t )
75 a g e a l l ( i n d t , : ) = age ;
76 s t a g e a l l ( i n d t , : ) = s t a g e ;
77 SYTO61 all ( i n d t , : ) = SYTO61 ;
78 end
79
80 w a i t b a r ( i / l e n g t h ( t ) )
81 end
82
83 c l o s e ( wb)
84
85 t o c
After running the above code, the following code is used to generate the result of Fig. 3 in the
main text.
25
1 f o r kk = 1 : 5 ;
2
3 b i n e d g e = 0 : 0 . 2 : 4 8 ;
4
5 y d a t a a g e = h i s t c o u n t s ( a g e a l l ( kk , : ) , b i n e d g e ) ;
6 temp = a g e a l l ( kk , : ) ;
7 temp1 = s t a g e a l l ( kk , : ) ;
8 t r o p h a g e = temp ( temp1 ==3) ;
9 y d a t a t r o g h a g e = h i s t c o u n t s ( t r o p h a g e , b i n e d g e ) ;
10
11
12 % f o r p l o t on ly
13 xnodes = z e r o s ( 1 , 2∗ l e n g t h ( b i n e d g e ) ) ;
14 xnodes ( 1 : 2 : end ) = b i n e d g e ;
15 xnodes ( 2 : 2 : end ) = b i n e d g e ;
16
17 ynodes = z e r o s ( 1 , 2∗ l e n g t h ( b i n e d g e ) ) ;
18 ynodes ( 2 : 2 : end−1) = y d a t a a g e ;
19 ynodes ( 3 : 2 : end−1) = y d a t a a g e ;
20
21 ynodes1 = z e r o s ( 1 , 2∗ l e n g t h ( b i n e d g e ) ) ;
22 ynodes1 ( 2 : 2 : end−1) = y d a t a t r o g h a g e ;
23 ynodes1 ( 3 : 2 : end−1) = y d a t a t r o g h a g e ;
24
25 f i g u r e ( 1 )
26 s u b p l o t ( 5 , 2 , 1 + 2∗ ( kk−1) )
27 p l o t ( xnodes , ynodes1 , ’− ’ , ’ l i n e w i d t h ’ , 2 , ’ c o l o r ’ , [ 0 1 0 ] )
28 ho ld on
29 p l o t ( xnodes , ynodes , ’− ’ , ’ l i n e w i d t h ’ , 2 , ’ c o l o r ’ , [ 0 0 0 ] )
30
31 % x l a b e l ( ’ p a r a s i t e age ( h p . i . ) ’ )
32 % y l a b e l ( ’ No . o f e v e n t s ’ )
33 box o f f
34
35 s e t ( gca , ’ x l im ’ , [ 1 6 3 0 ] , ’ y l im ’ , [ 0 5 0 0 ] , ’ f o n t s i z e ’ , 1 4 )
36 s e t ( gca , ’ T i c k D i r ’ , ’ o u t ’ , ’ L ineWidth ’ , 2 )
37 s e t ( gca , ’ t i c k l e n g t h ’ , [ 0 . 0 2 0 . 0 1 ] )
38 t e x t ( 2 0 , 2 0 0 , [ ’ mean p a r a s i t e age = ’ , num2s t r ( t i m e t o r e c o r d
( kk ) +10) , ’ h p . i . ’ ] , ’ f o n t s i z e ’ , 1 4 )
39
40
41 % SYTO f l u o h i s t o g r a m
42
43 b i n e d g e = exp ( l i n s p a c e ( l o g ( min ( SYTO61 all ( kk , : ) ) ) , l o g ( max
( SYTO61 all ( kk , : ) ) ) , 5 0 ) ) ;
44
45 y d a t a = h i s t c o u n t s ( SYTO61 all ( kk , : ) , b i n e d g e ) ;
46
26
47 temp = SYTO61 all ( kk , : ) ;
48 temp1 = s t a g e a l l ( kk , : ) ;
49 t r o p h f l u o = temp ( temp1 ==3) ;
50 y d a t a t r o g h f l u o = h i s t c o u n t s ( t r o p h f l u o , b i n e d g e ) ;
51
52 % f o r p l o t on ly
53 xnodes = z e r o s ( 1 , 2∗ l e n g t h ( b i n e d g e ) ) ;
54 xnodes ( 1 : 2 : end ) = b i n e d g e ;
55 xnodes ( 2 : 2 : end ) = b i n e d g e ;
56
57 ynodes = z e r o s ( 1 , 2∗ l e n g t h ( b i n e d g e ) ) ;
58 ynodes ( 2 : 2 : end−1) = y d a t a ;
59 ynodes ( 3 : 2 : end−1) = y d a t a ;
60
61 ynodes1 = z e r o s ( 1 , 2∗ l e n g t h ( b i n e d g e ) ) ;
62 ynodes1 ( 2 : 2 : end−1) = y d a t a t r o g h f l u o ;
63 ynodes1 ( 3 : 2 : end−1) = y d a t a t r o g h f l u o ;
64
65 s u b p l o t ( 5 , 2 , 2∗ kk )
66 s e m i l o g x ( xnodes , ynodes1 , ’− ’ , ’ l i n e w i d t h ’ , 2 , ’ c o l o r ’ , [ 0 1 0 ] )
67 ho ld on
68 s e m i l o g x ( xnodes , ynodes , ’− ’ , ’ l i n e w i d t h ’ , 2 , ’ c o l o r ’ , [ 0 0 0 ] )
69
70 % x l a b e l ( ’SYTO−61 f l u o r e s c e n c e ’ )
71 box o f f
72
73 s e t ( gca , ’ x l im ’ , [ 1 0 0 0 100000] , ’ y l im ’ , [ 0 4 0 0 ] , ’ f o n t s i z e ’ , 1 4 )
74 s e t ( gca , ’ T i c k D i r ’ , ’ o u t ’ , ’ L ineWidth ’ , 2 )
75 s e t ( gca , ’ t i c k l e n g t h ’ , [ 0 . 0 2 0 . 0 1 ] )
76 end
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The model used to simulate in vivo parasite clearance
Here we propose a simple two-compartment model to capture both parasite killing and transi-
tion from rings to trophozoites. For a certain age a, we denote the number of live rings by R
and the number of live trophozoites by T . Then the equation governing the dynamics of R, T
and a are given by
dR
dt =−krR−λR, (S1)
dT
dt = λR− ktT, (S2)
da
dt = 1, (S3)
where the term λR represents the rate of conversion from rings to trophozoites at the population
level. Since we assume the transition can only occur after age Ar (Ar = 21 h p.i. is assumed in
the simulation), λ takes
λ =
{
0, a < Ar
22
34+C , a≥ Ar
(S4)
where C is DHA concentration. The hyperbolic relationship is used to model a hypothetical
property that a higher drug concentration would lead to a stronger delay in parasite growth. kr
and kt are drug-induced parasite killing rates for rings and trophozoites respectively. In order
to capture that killing rate for rings is significantly smaller than that for trophozoites [7,16,17],
we choose
kr =
0.5C2
C2 +2002 , (S5)
kt =
2C2
C2 +2002 . (S6)
To model the pharmacokinetic profile where plasma DHA concentration usually follows a
biphasic behaviour [16], we use
dC
dt =
{ Cmax
tm
, t < tm
− ln(2)t1/2 C, t ≥ tm
(S7)
where Cmax is the maximum achievable concentration and tm indicates the time (since drug
application) when the maximum concentration is achieved. The in vivo DHA half-life t1/2 =
0.9 h [9]. To simulate the case of a single dose of artesunate (2mg/kg), we assume Cmax =
2820 nM and tm = 1 h [2, 9].
To assess the effect of growth retardation on parasite clearance, we consider two scenarios,
drug-dependent λ and drug-independent λ . The former is modelled by using Eq. S4 while
the latter is modelled by fixing C to be zero in Eq. S4 (i.e. assuming constant λ = 22/34 =
0.647 h−1 for a≥ Ar).
To simulate the model, we initially distribute 1011 parasites into 20 age bins from age 1 h
p.i. to 20 h p.i. (we only consider integer ages) following a normal distribution with a mean
of 10 h p.i. and a standard deviation of 2 h p.i. (see Fig. 12 in the main text). For each age
group, we use MATLAB’s bulit-in solver ode15s to solve the model and obtain the time series
of T +R. Then the time series of total number of live parasites is given by the sum of all 20
time series (result is shown in Fig. 12 in the main text). Moreover, we can also obtain the age
distribution at any time (an example of t = 20 h is given in Fig. 12 in the main text). MATLAB
code is provided in the next section.
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MATLAB code for solving the model of in vivo parasite clearance
1 c l e a r
2 t i c
3
4 d r u g a p p t i m e = 1 0 ; % t im e of drug a p p l i c a t i o n
5
6 t h = 0 . 9 ; % i n v ivo DHA h a l f− l i f e
7
8 i n i t a g e =10+2∗ r andn (1 e +11 ,1 ) ; % i n i t i a l ages o f t h e 10ˆ11
p a r a s i t e s
9 a g e d i s = h i s t c o u n t s ( i n i t a g e , 0 : 1 : 2 0 ) ; % i n i t i a l age
d i s t r i b u t i o n
10 age = 1 : 2 0 ; % age b i n s
11
12 t = 0 : 0 . 0 1 : 3 0 ;
13
14 % c a l c u l a t e t h e t im e s e r i e s o f DHA c o n c e n t r a t i o n
15 t 1 = t ( t<d r u g a p p t i m e ) ; % t im e b e f o r e drug a p p l i c a t i o n
16 t 3 = t ( t>=d r u g a p p t i m e +1) ; % d e c r e a s i n g phase o f PK p r o f i l e
17 t 2 = i n t e r s e c t ( s e t d i f f ( t , t 1 ) , s e t d i f f ( t , t 3 ) ) ; % i n c r e a s i n g
phase o f PK p r o f i l e
18 C1 = 0∗ t 1 ;
19 C2 = 2 8 2 0 / 1∗ ( t2−d r u g a p p t i m e ) ;
20 C3 = C2 ( end ) ∗ exp(− l o g ( 2 ) / t h ∗ ( t3−t 2 ( end ) ) ) ;
21 C = [ C1 , C2 , C3 ] ; % f u l l d rug c o n c e n t r a t i o n p r o f i l e
22
23 Numt = ones ( l e n g t h ( age ) , l e n g t h ( t ) ) ; % m a t r i x f o r t o t a l number
o f p a r a s i t e s
24 Numt ( : , 1 ) = a g e d i s ’ ; % a s s i g n t h e i n i t i a l age d i s t r i b u t i o n
25
26 wb= w a i t b a r ( 0 , ’ p l e a s e w a i t . . . ’ ) ;
27
28 f o r kk =1: l e n g t h ( age )
29 i n i t = [ a g e d i s ( kk ) ; 0 ; age ( kk ) ; 0 ] ;
30 f o r i =2: l e n g t h ( t )
31 [ ˜ , So l ] = ode15s ( @invivo sim , [ 0 0 . 0 1 ] , i n i t ) ;
32 i n i t = [ So l ( end , 1 : 3 ) ’ ;C( i −1) ] ;
33 Numt ( kk , i ) = So l ( end , 1 ) + So l ( end , 2 ) ;
34 end
35 w a i t b a r ( kk / l e n g t h ( age ) )
36 end
37
38 c l o s e ( wb)
39 t o c
40 c l e a r i n i t a g e % remove l a r g e v e c t o r t o r e l e a s e memory
where the function invivo sim appearing in the command of ode15s is given by
29
1 f u n c t i o n dy = i n v i v o s i m ( ˜ , y )
2
3 % y = [ r i n g ; t r o p h ; age ;DHA c o n c e n t r a t i o n ]
4
5 kr =0 .5∗ y ( 4 ) ˆ 2 / ( y ( 4 ) ˆ 2 + 2 0 0 ˆ 2 ) ;
6 k t =2∗y ( 4 ) ˆ 2 / ( y ( 4 ) ˆ 2 + 2 0 0 ˆ 2 ) ;
7
8 a l t =1; % drug−d e p e n d e n t r i n g−to−t r o p h t r a n s i t i o n r a t e
9 % s e t a l t =0 f o r a drug−i n d e p e n d e n t r i n g−to−t r o p h t r a n s i t i o n
r a t e
10
11 i f y ( 3 )>=21
12 lambda = 2 2 / ( 3 4 + a l t ∗y ( 4 ) ) ;
13 e l s e
14 lambda = 0 ;
15 end
16
17 dy = z e r o s ( 4 , 1 ) ;
18
19 dy ( 1 ) = −kr ∗y ( 1 )−lambda ∗y ( 1 ) ;
20 dy ( 2 ) = lambda ∗y ( 1 )−k t ∗y ( 2 ) ;
21 dy ( 3 ) = 1 ;
22 dy ( 4 ) = 0 ;
30
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Figure S1: Experimental data of SYTO-61 fluorescence frequency histograms with various DHA con-
centrations (note that two cultures with 0 nM DHA were measured). For each panel, samples with
fluorescence less than 3000 (indicated by the dashed lines) were considered to include fluorescence sig-
nals from uninfected RBC and were thus not included in model fitting process. Note that the histograms
are corrected by removing the unviable population (see Materials and Methods for details).
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Figure S2: No systematic bias is evidenced for the simulated histogram data-based parameter estima-
tion. In Fig. 11 in the main text, a weak underestimation of K3 and K4 is observed. To examine whether
it is due to error in simulated histogram data (4000 samples for each histogram) or bias in the method
of parameter estimation, we performed 100 trials, for each of which a set of simulated histogram data
similar to Fig. 10 (generated by using the same model parameters given in Table S3) and the parameters
K1–K5 were estimated using the same method. The figures show both the true parameter values (which
are the same for the 100 trials) and the mean and SD of the estimates of the 100 trials for each parameter.
Note that the error bars here represent mean±SD of the 100 estimates from the 100 trials rather than the
an single estimate and 95% CI presented in Fig. 11 in the main text. The results show that the estimates
are very consistent with the true values, suggesting nearly no systematic bias (relative bias < 1.03% in
this test) is induced by the fitting method.
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Figure S3: Simulated data with both true distribution and best-fit distribution. 4000 samples were used
for each of histograms, approximating the sample size of experimental data. The values of Ar and λ
used to generate the simulated data are indicted in each panel and the other parameters are provided in
Table S4.
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Figure S4: Comparison of best-fit parameter values and the true values for simulated data shown in Fig.
S3. Error bars indicate 95% CIs of the estimates. Full fitting results are given in Supplementary Table
S4.
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Figure S5: Simulated data with both true distribution and best-fit distribution. 4000 samples were used
for each of histograms, approximating the sample size of experimental data. The values of Ar and λ
used to generate the simulated data are indicted in each panel and the other parameters are provided in
Table S5.
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Figure S6: Comparison of best-fit parameter values and the true values for simulated data shown in Fig.
S5. Error bars indicate 95% CIs of the estimates. Full fitting results are given in Supplementary Table
S5.
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Figure S7: Simulated data with both true distribution and best-fit distribution. 4000 samples were used
for each of histograms, approximating the sample size of experimental data. The values of Ar and λ
used to generate the simulated data are indicted in each panel and the other parameters are provided in
Table S6.
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Figure S8: Comparison of best-fit parameter values and the true values for simulated data shown in Fig.
S7. Error bars indicate 95% CIs of the estimates. Full fitting results are given in Supplementary Table
S6.
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Supplementary tables
Table S1: The result of fitting the model to experimental histogram data (ART). The initial point
generating the best-fit parameters is given by K1 = 9 (16 repeated parameters), K2 = 0.3 (16 repeated
parameters), K3 = 8, K4 = 2 and K5 = 2.
ART conc. (nM)
Parameter estimate (95% CI)
K1 K2 Other parameters
0 9.1501 (9.1232, 9.1771) 0.3287 (0.3068, 0.3506)
K3 = 8.6861
(8.6715, 8.7006);
K4 = 16.6432
(11.5799, 21.7065);
K5 = 1.6048
(1.5330, 1.6767).
0 9.2022 (9.1734, 9.2310) 0.3192 (0.2978, 0.3406)
1.2 9.1868 (9.1591, 9.2145) 0.3102 (0.2896, 0.3308)
2.4 9.1843 (9.1560, 9.2126) 0.3293 (0.3072, 0.3514)
4.9 9.1825 (9.1549, 9.2100) 0.3168 (0.2957, 0.3378)
9.8 9.1510 (9.1235, 9.1785) 0.3422 (0.3197, 0.3647)
19.5 9.1355 (9.1085, 9.1625) 0.3469 (0.3237, 0.3702)
39.1 9.0883 (9.0615, 9.1150) 0.3598 (0.3355, 0.3840)
78.1 9.0377 (9.0118, 9.0637) 0.3703 (0.3451, 0.3954)
156.3 9.0183 (8.9930, 9.0435) 0.3613 (0.3372, 0.3855)
312.5 8.9805 (8.9576, 9.0034) 0.3572 (0.3346, 0.3798)
625 8.9693 (8.9483, 8.9903) 0.3445 (0.3232, 0.3659)
1250 8.9400 (8.9178, 8.9622) 0.3561 (0.3338, 0.3785)
2500 8.9094 (8.8891, 8.9297) 0.3500 (0.3291, 0.3708)
5000 8.8730 (8.8529, 8.8930) 0.3557 (0.3352, 0.3763)
10000 8.8582 (8.8398, 8.8766) 0.3340 (0.3151, 0.3529)
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Table S2: The result of fitting the model to experimental histogram data (DHA). The initial point
generating the best-fit parameters is given by K1 = 9 (16 repeated parameters), K2 = 0.3 (16 repeated
parameters), K3 = 8, K4 = 4 and K5 = 2.
DHA conc. (nM)
Parameter estimate (95% CI)
K1 K2 Other parameters
0 9.1011 (9.0727, 9.1294) 0.2816 (0.2599, 0.3033)
K3 = 8.6243
(8.6084, 8.6402);
K4 = 12.3188
(9.1899, 15.4477);
K5 = 1.7590
(1.6677, 1.8502).
0 9.1343 (9.1044, 9.1642) 0.2884 (0.2660, 0.3107)
0.12 9.1425 (9.1122, 9.1729) 0.2908 (0.2682, 0.3134)
0.24 9.1340 (9.1049, 9.1631) 0.2886 (0.2670, 0.3103)
0.5 9.1305 (9.1006, 9.1605) 0.2872 (0.2648, 0.3096)
1 9.1151 (9.0855, 9.1446) 0.2960 (0.2730, 0.3190)
2 9.1054 (9.0762, 9.1346) 0.2981 (0.2750, 0.3212)
3.9 9.0752 (9.0463, 9.1041) 0.3069 (0.2830, 0.3308)
7.8 9.0556 (9.0273, 9.0839) 0.3075 (0.2832, 0.3319)
15.6 9.0204 (8.9925, 9.0483) 0.3227 (0.2977, 0.3477)
31.3 8.9084 (8.8837, 8.9331) 0.3408 (0.3159, 0.3656)
62.5 8.8085 (8.7886, 8.8283) 0.3136 (0.2934, 0.3339)
125 8.6865 (8.6649, 8.7080) 0.3328 (0.3131, 0.3525)
250 8.6622 (8.6427, 8.6817) 0.3248 (0.3071, 0.3425)
500 8.6079 (8.5892, 8.6266) 0.3063 (0.2908, 0.3218)
1000 8.7061 (8.6912, 8.7209) 0.2640 (0.2491, 0.2789)
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Table S3: Comparison between the fitting results and the true parameter values used to generate
the simulated data shown in Fig. 10 in the main text. The initial point generating the best-fit param-
eters is given by K1 = 9, K2 = 0.2, K3 = 8 (4 repeated parameters), K4 = 2 (4 repeated parameters) and
K5 = 3.
Parameter Estimate 95% CI True value Corresponding true model parameter
K1 8.7572 (8.7499, 8.7644) 8.7557 F0 = 20, r1 = 0.24, µ = 24
K2 0.1494 (0.1423, 0.1564) 0.1440 σ = 0.6, r1 = 0.24
K3 7.9702 (7.8422, 8.0982) 8.0357 F0 = 20, r1 = 0.24, Ar = 21
K3 7.9939 (7.8759, 8.1119) 8.0357 F0 = 20, r1 = 0.24, Ar = 21
K3 7.9848 (7.8660, 8.1035) 8.0357 F0 = 20, r1 = 0.24, Ar = 21
K3 8.0013 (7.8823, 8.1202) 8.0357 F0 = 20, r1 = 0.24, Ar = 21
K4 1.0746 (0.8548, 1.2944) 1.2500 r1 = 0.24, λ = 0.3
K4 2.3377 (1.8877, 2.7877) 2.5000 r1 = 0.24, λ = 0.6
K4 3.3622 (2.6702, 4.0542) 3.7500 r1 = 0.24, λ = 0.9
K4 4.8077 (3.6120, 6.0031) 5.0000 r1 = 0.24, λ = 1.2
K5 2.2561 (2.0861, 2.4260) 2.3333 r1 = 0.24, r2 = 0.56
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Table S4: Comparison between the fitting results and the true parameter values used to generate
the simulated data shown in Fig. S3. The initial point generating the best-fit parameters is given by
K1 = 9, K2 = 0.2, K3 = 9 (4 repeated parameters), K4 = 2 (4 repeated parameters) and K5 = 3.
Parameter Estimate 95% CI True value Corresponding true model parameter
K1 8.7572 (8.7538, 8.7606) 8.7557 F0 = 20, r1 = 0.24, µ = 24
K2 0.1452 (0.1416, 0.1489) 0.1440 σ = 0.6, r1 = 0.24
K3 6.6771 (6.5006, 6.8537) 6.5957 F0 = 20, r1 = 0.24, Ar = 15
K3 7.3726 (7.2536, 7.4915) 7.3157 F0 = 20, r1 = 0.24, Ar = 18
K3 8.0640 (7.9957, 8.1323) 8.0357 F0 = 20, r1 = 0.24, Ar = 21
K3 8.7345 (7.9957, 8.7901) 8.7557 F0 = 20, r1 = 0.24, Ar = 24
K4 2.3022 (2.0296, 2.5748) 2.0833 r1 = 0.24, λ = 0.5
K4 2.1793 (1.9382, 2.4203) 2.0833 r1 = 0.24, λ = 0.5
K4 2.1407 (1.8693, 2.4122) 2.0833 r1 = 0.24, λ = 0.5
K4 1.8049 (0.8657, 2.7440) 2.0833 r1 = 0.24, λ = 0.5
K5 2.3748 (2.2617, 2.4878) 2.3333 r1 = 0.24, r2 = 0.56
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Table S5: Comparison between the fitting results and the true parameter values used to generate
the simulated data shown in Fig. S5. The initial point generating the best-fit parameters is given by
K1 = 9, K2 = 0.2, K3 = 8 (4 repeated parameters), K4 = 3 (4 repeated parameters) and K5 = 3.
Parameter Estimate 95% CI True value Corresponding true model parameter
K1 8.7549 (8.7509, 8.7590) 8.7557 F0 = 20, r1 = 0.24, µ = 24
K2 0.1474 (0.1442, 0.1506) 0.1440 σ = 0.6, r1 = 0.24
K3 7.2199 (7.0792, 7.3606) 7.3157 F0 = 20, r1 = 0.24, Ar = 18
K3 7.7435 (7.6476, 7.8395) 7.7957 F0 = 20, r1 = 0.24, Ar = 20
K3 8.2598 (8.1946, 8.3250) 8.2757 F0 = 20, r1 = 0.24, Ar = 22
K3 8.8085 (8.7722, 8.8448) 8.7557 F0 = 20, r1 = 0.24, Ar = 24
K4 4.2809 (3.5036, 5.0583) 5.0000 r1 = 0.24, λ = 1.2
K4 3.9442 (3.2968, 4.5917) 4.1667 r1 = 0.24, λ = 1
K4 3.0947 (2.4884, 3.7009) 3.3333 r1 = 0.24, λ = 0.8
K4 5.0574 (2.2743, 7.8405) 2.5000 r1 = 0.24, λ = 0.6
K5 2.2694 (2.1635, 2.3754) 2.3333 r1 = 0.24, r2 = 0.56
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Table S6: Comparison between the fitting results and the true parameter values used to generate
the simulated data shown in Fig. S7. The initial point generating the best-fit parameters is given by
K1 = 9, K2 = 0.2, K3 = 9 (4 repeated parameters), K4 = 2 (4 repeated parameters) and K5 = 3.
Parameter Estimate 95% CI True value Corresponding true model parameter
K1 8.7520 (8.7482, 8.7558) 8.7557 F0 = 20, r1 = 0.24, µ = 24
K2 0.1458 (0.1425, 0.1491) 0.1440 σ = 0.6, r1 = 0.24
K3 8.7630 (8.7399, 8.7862) 8.7557 F0 = 20, r1 = 0.24, Ar = 24
K3 8.2444 (8.1862, 8.3026) 8.2757 F0 = 20, r1 = 0.24, Ar = 22
K3 7.7834 (7.6986, 7.8681) 7.7957 F0 = 20, r1 = 0.24, Ar = 20
K3 7.2919 (7.1706, 7.4133) 7.3157 F0 = 20, r1 = 0.24, Ar = 18
K4 5.6203 (3.7485, 7.4921) 5.0000 r1 = 0.24, λ = 1.2
K4 3.8541 (3.1739, 4.5343) 4.1667 r1 = 0.24, λ = 1
K4 3.3537 (2.9171, 3.7903) 3.3333 r1 = 0.24, λ = 0.8
K4 2.4964 (2.2040, 2.7889) 2.5000 r1 = 0.24, λ = 0.6
K5 2.3139 (2.2106, 2.4172) 2.3333 r1 = 0.24, r2 = 0.56
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